Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-CWS + HAIC + Lenvatinib + Tislelizumab in Advanced HCC
NCT05533892Phase 1Recruiting
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nocardia rubra cell wall skeleton in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), gallbladder carcinoma and 1 more. Primary endpoint: Objective Response Rate at 6 months. Started Sep 2022; status: recruiting.
02
Drugs
nocardia rubra cell wall skeleton
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)gallbladder carcinomaampullary carcinoma
Beyond the preview
Go deeper on NCT05533892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533892.